Mutated peptide compounds, derived from hsp70, useful in cancer immunotherapy
AssigneeInstitut Gustave Roussy
InventorsFrédéric Triebel, Catherine Gaudin
Life of this patent
Estimating the term…
Abstract
The invention concerns a method for identifying peptide compounds derived from hsp70, having at least one mutation relative to the hsp70 natural sequence, said compounds bringing about a response T specific of tumours, and the peptide compounds obtainable by said method. The invention also concerns the use of said peptide compounds for performing repeated immunization in a subject so as to interrupt immune tolerance for the corresponding natural (non-mutated) peptide. Said peptide compounds are useful for preparing a medicine designed in particular for treating cancer optionally in combination with any agent provoking tumour cell stress.
Claims8
A peptide compound comprising the amino acid sequence of SLFEGIDIY (SEQ ID No:
- 1) or SLFEGIDIYT (SEQ ID No:
- 2).
Dependencies are inferred from the claim text.